期刊
JOURNAL OF CELLULAR PHYSIOLOGY
卷 234, 期 10, 页码 17549-17560出版社
WILEY
DOI: 10.1002/jcp.28378
关键词
MAPK; osteoclast; osteolysis; therapeutics; vitexin
资金
- Zhejiang Basic Public Welfare Research Project [LGF18H060010]
- Projects of Medical and Health Technology Development Program in Zhejiang Province [2018KY824]
- National Natural Science Foundation of China [81572126, 81871801]
Osteolytic diseases are characterized by an increase in the number and/or activity of bone-resorbing osteoclasts. Identification of natural compounds that can suppress osteoclast formation and function is crucial for the prevention and treatment of osteolytic diseases. Vitexin, a naturally-derived flavonoid extracted from various medicinal plant species, demonstrates a broad range of pharmacological properties including anticancer and anti-inflammatory effects. Here in this study, we showed that vitexin exerts antiosteoclastogenic effects by directly inhibiting receptor activator of nuclear factor-kappa B ligand (RANKL)-induced osteoclast formation and bone resorption in vitro and protected against lipopolysaccharide (LPS)-induced inflammatory osteolysis in vivo. Vitexin suppressed the early activation of ERK and p38 MAPK pathways in response to RANKL thereby attenuating the downstream induction of c-Fos and NFATc1, and abrogating the expression of osteoclast marker genes. Collectively, these results provide evidence for the therapeutic application of vitexin in the treatment of osteoclast-mediated bone lytic diseases.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据